EP PerMed
European Partnership
for **Personalised Medicine**

Research, Innovation and Technology Call (2026)

Test and Demonstration of Multimodal Data Approaches for Personalised Medicine ("MultiPMData2026")

(EP PerMed Grant 101137129)

Guidelines for Applicants

Important Deadlines

Submission of pre-proposals: 12 January 2026 at 14:00 (CET)

Submission of invited full proposals: 27 April 2026 at 14:00 (CEST)

Link to the electronic proposal submission tool:

https://ptoutline.eu/app/eppermedRITC2026

For further information, please visit our website: www.eppermed.eu

or contact the EP PerMed Joint Call Secretariat (JCS)

The French National Research Agency
86 rue Regnault, 75013 Paris
Mylène Vaillancourt, Dr. Mérick Machouri
Phone: +33 1 78 09 80 36, +33 1 72 73 06 72
EPPerMed@agencerecherche.fr

Co-funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Table of contents

1 Background

The **European Partnership for Personalised Medicine, EP PerMed**, serves as a platform for the joint programming of national and European regional research and innovation (R&I) activities. It implements the Strategic Research and Innovation Agenda (SRIA) for Personalised Medicine (2023)[1] through targeted funding for research, development, and innovation.

By supporting transnational collaborative R&I projects, EP PerMed aims to strengthen cooperation among stakeholders across Europe and beyond. This joint effort helps to maximise the impact of personalised medicine (PM) by pooling resources and enabling large-scale investments in the field.

To align regional and national research strategies and funding activities, promote excellence, and strengthen the competitiveness of European and international stakeholders in PM R&I – while fostering EU cooperation and enhancing collaboration with non-EU countries – 19 funding organisations have agreed to launch the Research, Innovation and Technology Call (RITC) 2026. This call supports collaborative innovation projects in PM and is co-funded by the European Union (EU).

The participating funding organisations particularly aim to encourage innovative, interdisciplinary public-private partnerships and to support the translational and clinical implementation of research outcomes.

EP PerMed will in this call fund innovation projects in human health that focus on test and demonstration of multimodal data for PM approaches, aiming to provide **more efficient and personalised management of patients with multimorbidity – defined as individuals living with two or more chronic diseases requiring management, as defined** in the text box below.

In this call, **a chronic disease is defined as a long-term health condition lasting 6 months or more, requiring management and significantly affecting health or activities of daily living**. Chronic diseases include, but are not limited to, the following categories:

- Cardiovascular
- Metabolic
- Respiratory
- Neurological
- Immunological (including autoimmune)
- Gastrointestinal
- Uro-genital
- Cancer
- Mental health disorders

Funded projects are required to test and further develop innovative solutions in **controlled real-world environments**. Proposals must present a comprehensive strategy detailing how the project aligns with the call scope in the collection, processing, and use of multimodal health data. This call promotes a holistic systems approach, emphasising the integration of six key enabling elements. These

[1] **https://www.eppermed.eu/action-areas/sria/**

elements are designed to lower the threshold for future implementation of innovative solutions into routine clinical practice.

The transnational consortia are **requested to include at least one enterprise of any size (SME or industry) as well as one clinical partner (also see call text section 7, B. Funding recipients).**

The rationale and aims of the RITC2026 are outlined in detail in the call text.

2 Application

Research project consortia who intend to submit a transnational proposal should register at **https://ptoutline.eu/app/eppermedRITC2026**, Click on "**sign up**" and follow the instructions. To register, please complete the different sections as soon as possible.

3 Proposal submission

Before starting your proposal, please carefully read the call text, including the central eligibility criteria and the regional/national eligibility and budgetary requirements (outlined in the annexes of this document), to ensure that you meet all formal requirements of the call.

A two-stage submission and evaluation process will be used for joint applications, consisting of a pre-proposal stage and a full proposal stage. In both stages, a single joint proposal (in English) must be prepared by the partners of the transnational consortium and submitted by one designated spokes-person, the coordinator, via the electronic submission system: **https://ptoutline.eu/app/eppermedRITC2026**.

Joint proposals consist of two components:

1) The pre- and full proposal template, provided in word format and used by applicants to describe the planned work, and
2) The electronic submission tool where mainly partner information details and financial plans are entered.

Both components must be completed collaboratively by all consortium partners and initiated in a timely manner.

Please use the pre-proposal template provided on the EP PerMed website (**www.eppermed.eu**) and the full proposal form sent to coordinators by the Joint Call Secretariat in the second stage, complete all fields, and respect the format of each section (DIN-A4, Segoe UI, size 10, single-spaced) as well as stated page limits. Only proposals using the official templates will be accepted.

In addition, the proposal, in a digitally signed PDF-format file or with a scanned version of the original signature page, to be uploaded to the online tool, must not exceed **8 Megabytes**. Proposals exceeding these limitations will be rejected by the online system.

Deadline to submit pre-proposals: **12 January 2026 (14:00, CET)**

Deadline to submit full proposals: **27 April 2026 (14:00, CEST)**

After these deadlines, the electronic submission system will not accept proposals and it will not be possible to amend the proposal or to add further documents.

Please note: The online system may be overloaded on the day of the deadline. Therefore, it is recommended to complete the online forms and upload the proposal in proper time.

In case of inconsistencies between the information registered in the online submission tool and the information included in the PDF of this application form, the information registered in the submission tool shall prevail.

For applicants from some regions/countries it may be required to submit the proposal or other information, before the deadline of this call, directly to their relevant regional/national funding organisation. Therefore, **applicants are strongly advised to verify the respective regional/country-specific funding organisation regulations and other specific information (see annex III of this document)**. For more details, applicants should also get in touch with the respective funding organisations contact persons (see annex I of this document). For central and additional information, please contact the Joint Call Secretariat.

Please Note:

It is mandatory to meet the deadline and to follow the format of the proposal structure.

The Joint Call Secretariat will check the proposals submitted to ensure that they meet the call's formal criteria **(e.g. date of submission; number of participating countries; eligibility of the coordinator; type of project partner; inclusion of all necessary information in English and appropriate limits on length).** In parallel, the Joint Call Secretariat will forward the proposals to the relevant regional/national funding organisations that will perform a formal check of compliance with their respective eligibility criteria. **Proposals not meeting the formal central or regional/national eligibility criteria will be rejected**. Proposals passing both checks will be forwarded to independent international scientific experts for evaluation.

For potential project consortium coordinators, it is recommended to read the EP PerMed funding organisations' eligibility criteria when looking for potential project consortium partners.

Bearing in mind that most of the management activities take up most of the coordinator's time and given the complexity of the research projects and the number of regions/countries usually involved, project coordinators are reminded of the importance of a well-designed and feasible work plan. Those actions will require that sufficient time is allocated to the project coordinator and also involved principle investigators even before the actual project starting date, e.g. for setting up the project consortium and recruiting the necessary personnel.

Project partners are **strongly advised to read the eligibility criteria of their respective funding organisations (see annex III of this document) and other requirements**, and to contact their respective funding agency prior to submitting the application (see also the call text and annex I of this document "List of Regional/National Contacts").

4 Eligible annexes in the pre- and full proposal stage

The following annexes are eligible. It is indicated in brackets at which stage of the call the documents have to be provided. All annexes are to be uploaded as separate files (not as annex to the proposal forms) via the electronic submission system:

- Annex 1 – Ethical self-assessment (**mandatory in the full proposal stage** – the template is provided with the full proposal form;
- Annex 2 – Description of the clinical research/study (if applicable), at full proposal stage – the template is provided with the full proposal form;
- Annex 3 – Description of animal research (if any), at full proposal stage – the template is provided with the full proposal form;
- Annex 4 – Letter of commitment for a project partner participating on own funds (if any; free format, at every stage; **mandatory in the full proposal stage**);
- Annex 5 – Supporting letters (at every stage) or endorsement letters (at every stage) in free format (if any);
- Annex 6 – The patient/citizen involvement plan describing the activities and methodologies for the involvement and providing information about the organisation. Submission of this annex is **highly recommended** for all applicants, and (**mandatory at both stages if funding for a patient/citizen representing organisation is requested directly from EP PerMed).** See annex II of this document regarding eligibility of these dedicated funds.

5 Fostering multidisciplinary & intersectoral collaboration

Despite significant progress in PM, its development and implementation remain complex. Multiple interdependent factors such as scientific, technological, ethical, economic, and societal must be addressed simultaneously. This requires collaboration across disciplines, sectors, and stakeholder groups, including researchers, clinicians, patients, public and private actors, and policy experts.

Consortia funded under this EP PerMed call are expected to be interdisciplinary and intersectoral, bringing together complementary expertise to ensure that PM solutions are scientifically robust, ethically sound, economically viable, and can be tested for real-world use. The following areas of expertise could be integrated into project teams. Please note that the list is not exhaustive.

- **Entrepreneurship** involves identifying unmet needs or gaps in markets, developing innovative solutions, and advancing them through stages such as securing financing, analysing market potential, and establishing and scaling a sustainable enterprise. The goal is to create value by delivering products or services that generate economic, social or cultural impact. Entrepreneurial aspects should be considered as early in development as possible- ideally during initial idea stages - to maximise the likelihood that research and concepts evolve into truly useful and impactful solutions.
- **Innovation/product development** refers to the process of transforming ideas and research findings into practical solutions that can reach end-users. For a technology or method intended for clinical application, significant refinement is required to ensure it can be reliably produced and delivered over extended periods in a manner that is financially sustainable.

- **Pre-clinical research** lays the scientific foundation for PM by exploring disease mechanisms at the molecular, cellular, and systems levels. It supports the identification of biomarkers, therapeutic targets, and mechanisms of resistance or variability in treatment response. This research is especially critical for developing tailored interventions for patients who do not respond to standard therapies. It also enables the stratification of patient populations, which is essential for designing effective clinical trials and personalised treatment pathways.
- **Clinical research** translates laboratory discoveries into patient care. It involves designing and conducting clinical studies or trials, validating biomarkers, and assessing safety, efficacy, and patient outcomes in diverse populations. A bidirectional, iterative relationship between clinical and pre-clinical research, such as in a Learning Health Systems, ensures that clinical needs inform research priorities and that research findings are rapidly integrated into practice. Clinician involvement is key to ensuring that innovations are relevant, feasible, and aligned with real-world care delivery.
- **Bioinformatics or Health Informatics:** These fields support the development of methods and technologies—such as multi-modal and Artificial Intelligence (AI)-driven algorithms—to predict treatment efficacy and adverse effects. Solutions should be scalable across diverse populations, including different age groups, genetic backgrounds, and socioeconomic contexts. Successful PM implementation depends on the integration of bioinformatics tools, real-world health data, and ICT (information and communications technology or technologies) systems to enable secure, interoperable, and efficient data flow and analysis. Including bioinformatics expertise ensures attention to data quality, privacy, and compliance with FAIR[2] principles, General Data Protection Regulation (GDPR)[3], and national regulations. It also supports the development and application of standards for data storage, accessibility, and reuse.
- **ELSA research** addresses the societal dimensions of PM, including data privacy, informed consent, equity of access, and regulatory compliance. It ensures that innovations are developed and implemented in ways that are ethically sound and socially acceptable. This includes engaging patients, citizens, and caregivers in co-design processes, addressing algorithmic bias, and ensuring transparency in decision-making. ELSA research also supports the development of communication strategies that help patients understand the risks, benefits, and implications of participating in PM research and care.
- **Health economics research** evaluates the cost-effectiveness, affordability, and broader socioeconomic impact of PM approaches. It supports the development of economic models that inform reimbursement decisions, resource allocation, and long-term sustainability. This includes assessing clinical outcomes, quality of life, patient preferences, and healthcare system dynamics. Health economics is essential for demonstrating the value of PM across the full care continuum – from prevention and early diagnosis to treatment and follow-up, and for supporting its integration into routine care.

---

[2] findable, accessible, interoperable and reusable (FAIR): **http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-data-mgt_en.pdf**

[3] **https://gdpr-info.eu/**

- **Implementation research** investigates how PM innovations can be effectively adopted, integrated, and sustained in real-world healthcare systems. It identifies barriers (e.g. workflow disruption, lack of training) and enablers (e.g. leadership support, digital readiness), and evaluates strategies for successful implementation. Implementation research ensures that PM solutions are not only effective in theory but also practical, acceptable, and scalable in diverse healthcare contexts. It plays a critical role in bridging the gap between innovation and impact, especially when aligned with local system needs and capacities.

6 Patient and citizen involvement

Involving patient and citizen representatives in research and innovation projects already from early stages is imperative to the long-term success of developing and implementing PM. Advantages include:

- Providing a different and complementary perspective – consortia can benefit from the experiences of those using the solution or living with a health condition;
- Encouraging public and open dissemination of the outcomes, using clear and accessible language, and contents of information in material provided to the wider public;
- Helping to ensure that the methods proposed for the study are suitable and sensitive to the situations of study participants as well as end-users;
- Helping to ensure that the project and its outcomes are sound, acceptable and important to the patients and the public;
- Helping to increase the participation/recruitment of participants in studies;
- Helping to improve patient adherence to a therapy by identifying barriers to and strategies for medication adherence and predictors of compliance.

In addition, involving members of the public ensures that projects consider broader principles of citizenship, accountability and transparency. **The involvement of patient/citizen organisations in research proposals submitted is part of the evaluation.**

As outlined in the call text, EP PerMed is financially supporting the involvement of patient/citizen organisations as full consortium partners. The funding is limited to a total of 50.000 € per project over 3 years. For more information concerning the eligibility rules, please see annex II of this document. The development of a patient/citizen involvement plan is recommended for all applicants, but **mandatory in both stages if funding is requested from EP PerMed** (to be uploaded electronically as annex 6 of the application form; see also annex II of this document).

7 The enabling elements

This call promotes a holistic systems approach, emphasising the integration of six enabling elements. These elements are designed to lower the threshold for future implementation of innovative solutions into routine clinical practice. The elements are outlined below with illustrative examples for clarity. As stated in the call text, and in the pre-/full proposal forms, it is required to describe how each element

is integrated into the project. However, the sub-points (a, b, c…) are provided as examples and do not need to be addressed individually.

1. **Knowledge integration:**
   Projects should build upon existing knowledge while integrating new insights throughout their duration to support continuous improvement. The inclusion of research components such as implementation research is encouraged to strengthen evidence-based development and adaptation. Other examples are:
   a. Leverage existing knowledge from e.g. scientific literature, clinical guidelines, patient registries, and real-world data.
   b. Bridge knowledge gaps by generating new insights during the project and integrating them with existing frameworks.
   c. Promote cross-disciplinary learning by involving diverse expertise (e.g. genomics, data science, clinical practice, ethics).
   d. Ensure knowledge transfer to stakeholders, including healthcare professionals, patients, and policymakers.

2. **Technologies, products, methods and processes:**
   Projects should combine novel innovations and knowledge with existing tools, methods and organisational frameworks to ensure compatibility and interoperability. This integration enhances the overall impact and facilitates smoother adoption in clinical settings. Examples are:
   a. Assess current practices and identify how the innovation complements, replaces, or improves them.
   b. Ensure interoperability with existing digital tools, diagnostic platforms, or treatment protocols.
   c. Demonstrate added value in terms of efficiency, accuracy, patient outcomes, or cost-effectiveness.
   d. Plan for scalability and adaptability across different healthcare systems or population groups.

3. **Infrastructure utilisation**
   PM solutions should be designed to integrate with and enhance the infrastructures already in place. This may include:
   a. Clinical Infrastructure: Hospitals, primary care centres, diagnostic labs, and specialist clinics already have established workflows, equipment, and care pathways. PM solutions should be compatible with these settings, supporting seamless integration into routine care.
   b. Digital Infrastructure: Many countries and regions have invested in electronic health records (EHRs), health information exchanges, national health data platforms and European initiatives such as the European Health Data Space. PM innovations should align with these systems, ensuring interoperability, secure data sharing, and compliance with data protection regulations (e.g. GDPR[3]).

c. Research Infrastructure: Biobanks, genomic databases, clinical trial networks, and academic research centres provide valuable resources for data collection, validation, and collaboration.
d. Regional and National Resources: Publicly funded initiatives, such as regional innovation hubs, digital health accelerators, and national genomics centers offer platforms for piloting and scaling PM solutions.

4. Business and value model

A well-prepared business and value model is essential to ensure the long-term sustainability, scalability, and adoption of PM innovations. This model should not only demonstrate how the solution creates value for patients and healthcare systems but also outline how it could be financed, delivered, and maintained over time. Examples are:

a. Value Proposition: What specific problem does the solution solve? Who are the primary beneficiaries (e.g. patients, clinicians, payers)? What measurable benefits does it offer (e.g. improved outcomes, reduced costs, better patient experience)?
b. Competitive Landscape: What alternative solutions exist? How does your solution compare in terms of effectiveness, cost, usability, and integration? What is your unique selling point?
c. Revenue and Funding Model: How will the solution generate revenue (e.g. licensing, subscription, pay-per-use)? What are the short- and long-term funding strategies (e.g. public grants, venture capital, partnerships)? Is there a plan for transitioning from research funding to commercial or institutional funding?
d. Reimbursement Strategy: Will the solution be eligible for reimbursement under current healthcare financing systems? What evidence is needed to support reimbursement (e.g. cost-effectiveness, clinical utility)?
e. Cost Structure and Affordability: What are the development, implementation, and maintenance costs? Is the solution affordable for the intended users and healthcare systems? How will costs evolve as the solution scales?
f. Sustainability and Scalability: Can the solution be maintained and updated over time? What are the barriers to scaling (e.g. infrastructure, regulation, training)? How will the model adapt to different healthcare systems or regions?

5. Policies and regulations

Projects should show awareness of relevant policies and regulatory challenges. Projects must ensure regulatory and ethical compliance. Some points to consider ensuring legal and ethical compliance:

a. Identify relevant regulations, including data protection (e.g. GDPR[3]), medical device laws, and clinical trial requirements.
b. Ensure ethical alignment, particularly in handling sensitive data and patient consent.
c. Engage with regulators early to identify potential barriers and co-develop solutions.
d. Adapt the solution or advocate for policy change where necessary to enable implementation.

6. **Organisation, behaviour and values**
   Solutions should be adaptable to real-world organisational contexts. Proposals should consider behavioural factors and promoting transferability across settings and align with the values of healthcare professionals and patients to ensure sustainable adoption. Examples are:

   a. To assess organisational readiness, including leadership support, workflows, and resource availability.
   b. Understand behavioural drivers and barriers among clinicians, patients, and other users.
   c. Promote user-centred design to ensure the solution meets real needs and preferences.
   d. Address affordability and equity, ensuring the solution is accessible and acceptable across diverse populations.
   e. Foster trust and transparency, especially in how data is used and how decisions are made

8 Inclusion of sex/gender analysis/research or underrepresented populations

Applicants are strongly encouraged to integrate sex and gender research, as well as underrepresented populations (e.g. ethnic minorities), or underrepresented patient sub-groups, e.g. children or elderly, as well as social components, e.g. different economic, educational backgrounds, in proposals submitted to the EP PerMed call. This includes not only the consideration of **sex distribution of research teams and the distribution of roles in a consortium** (gender balance), but also the **inclusion of sex or gender research** *per-se* (sex and gender dimension). This applies especially when patients are involved in the proposal. A project is considered relevant in this context when it concerns individuals or groups of people or when its findings may affect individuals or groups.

Sex and gender represent key elements in research. In particular, gender equality shall be considered in two dimensions:

- Human resources: balance between women and men in the research teams;
- Research content: analysing and considering the differences between men/males and women/females in the research and innovation content of the projects.

The inclusion of gender or sex or underrepresented populations analysis is assessed in the evaluation of proposals and represents one evaluation sub-criterion in *"1. Excellence, e. Appropriate consideration of the gender dimension and sex aspects, underrepresented populations, or specific sub-groups in research and innovation content; f. Consideration of sex aspects and underrepresented populations in research teams, if applicable."*.

Applicants are encouraged to visit the following links and to complete the modules in order to increase the quality of their applications concerning the integration of sex and gender-based considerations:

a) Canadian Institute of Health Research "Online Training Modules: Integrating Sex & Gender in Health Research": **http://www.cihr-irsc.gc.ca/e/49347.html**

b) Gender Equality in Horizon Europe: **https://research-and-innovation.ec.europa.eu/strategy/strategy-2020-2024/democracy-and-rights/gender-equality-research-and-innovation_en#gender-equality-in-horizon-europe**

9 Data Open Access Policy

Applicants must clearly describe all tools, technologies, and digital supports to be used in the project, as well as the methodological approach. In addition, descriptions should be included of how data from different sources will be combined, how different data streams will be merged and how the primary outcomes will be meaningful across different sources. Proposals should explain how the data, tools, code or algorithms gathered, developed or used through the project will be maintained after the project end and would be available (findable, accessible, interoperable and re-usable) or communicated to the wider community, during and after the end of the project period.

In addition, EP PerMed requires proposals to include data management plans (DMPs) according to international state-of-the-art standards for data security [following the **FAIR principles[2], the General Data Protection Regulation (GDPR)[3] and in accordance with Ethical principles[4] for data management**]. The DMP represents an essential document for the implementation of the research and innovation, as it helps to define the responsibilities of research and innovation data management ahead of the start of the project. The consortia of projects selected for funding must submit a detailed DMP (template to be available: **www.eppermed.eu**). The project coordinator is responsible for sending the complete DMP to the JCS, within the six-month preparatory phase and an updated DMP at the end of the project together with the final scientific report. Compliance with or updates of the DMP must be reported in each annual scientific project progress report.

10 General data protection regulation

The following Data Privacy Notice applies:

By applying to the call, applicants consent to the use, processing and retention of their data, in line with the above notice and for the purposes of:

- processing and evaluating the application where processing shall be lawful - only if and to the extent that - processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller;
- administering any subsequent funding award;
- managing the funding organisation's relationship with the applicants;
- analysing and evaluating the call;
- reporting to the European Commission/ European Health and Digital Executive Agency (HaDEA) on the call;
- providing aggregate data to regional/national and European surveys and analyses;
- complying with audits that may be initiated by the funding organisations.

[4] **https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/how-to-complete-your-ethics-self-assessment_en.pdf**
http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/ethics/h2020_hi_ethics-data-protection_en.pdf

The members of the EP PerMed consortium may share an applicant's data with third parties (some of which may be based outside the European Economic Area) in relation to the above activities including evaluators, auditors and the European Commission (or its agencies).

The members of the EP PerMed consortium may link the data that applicants provide in the application with regional/national, bibliographic or external research funding data which is available through public subscription-based databases (e.g. Scopus, Web of Science, etc.) or other regional, national or open datasets. The members of the EP PerMed consortium may also link the data that applicants provide in their application with future data that applicants provide as part of the ongoing management and reporting.

Data on funding organisations including contact details of Call Steering Committee[5] (CSC) members are kept for the purpose of the call communication. The information will be published with prior consent of the respective management bodies.

11 Building your proposals

Please take note of the references below that could be helpful:

- Partnering options: A **partnering tool** is available for this call which provides a platform for interested users to search for collaboration partners: **https://www.b2match.com/e/online-match-making-eppermed-ritc26**
- European **Research Infrastructures/Platforms**:
  - Biobanking and Biomolecular Resources Research Infrastructure (BBMRI): **https://www.bbmri-eric.eu/**
  - The European Life Sciences Infrastructure for Biological Information (ELIXIR): **https://www.elixir-europe.org/personalised-medicine**
  - European Infrastructure for translational medicine (EATRIS): **http://eatris.eu/**
  - European Clinical Research Infrastructure Network (ECRIN): **http://www.ecrin.org/**
  - European High Capacity Screening Network (EU-Openscreen): **http://www.eu-openscreen.eu/**
  - European Infrastructure for Phenotyping, Archiving and Distribution of Mouse Models (INFRAFRONTIER): **https://www.infrafrontier.eu/**
  - Integrated Structural Biology Infrastructure for Europe (INSTRUCT): **http://www.structural-biology.eu/**
  - European Strategy Forum on Research Infrastructures (ESFRI): **https://www.esfri.eu/**
  - The European Intergovernmental Research Organisation forum (EIROforum): **https://www.eiroforum.org/about-eiroforum/**

[5] Call Steering Committee: comprises a single representative from each country's/region's funding organisation

  - Coordinated Research Infrastructures Building Enduring Life-science Services (CORBEL): **http://www.corbel-project.eu/services.html**

- Public engagement, open access, gender equality, science education, ethics and good governance should be considered. Please visit:
  - the **Responsible Research and Innovation** site of the European Commission: **https://rri-tools.eu/**
  - The Societal Readiness Thinking Tool – Guide for the steps of including RRI in a project: **https://thinkingtool.eu/**
  - EC Guide "How to complete your ethics self-assessment": **https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/how-to-complete-your-ethics-self-assessment_en.pdf**
- Recommendations concerning the involvement of competent authorities in research projects: **https://www.hma.eu/fileadmin/dateien/HMA_joint/00-_About_HMA/03-Working_Groups/EU-IN/2023_02_EU-IN_Involvement_of_competent_authorities_in_externally_funded_projects.pdf**
- Recommendations for patient engagement in research:
  - Patient Engagement Resource Centre: **https://patient-engagement.eu/**
  - Patient and next-of-kin collaboration for better research and healthcare: **https://biobanksverige.se/wp-content/uploads/2024/01/patient-and-next-of-kin-collaboration-for-better-research-and-healthcare-2-0.pdf**
- Helpdesk for **Intellectual Property (IP) Rights** issues: **https://www.iprhelpdesk.eu/**
- Inspiration for **managing IP Rights** through the DESCA model produced by the European innovation council: **https://www.desca-agreement.eu/desca-model-consortium-agreement/desca-models/**
- Information about a **harmonised Data Access Agreement (hDAA)** for sharing and using controlled access data, can be found here (EU-STANDS4PM): **https://www.eu-stands4pm.eu/data_access**
- Information about data reusability: **https://www.eppermed.eu/publications-resources/resources-for-researchers/data-reusability/**
- Support for the development of a **Data Management Plan** (see also section 9 of this document):
  - Science Europe:

    https://www.scienceeurope.org/media/4brkxxe5/se_rdm_practical_guide_extended_final.pdf

    https://www.scienceeurope.org/media/411km040/se-rdm-template-3-researcher-guidance-for-data-management-plans.docx
  - Horizon 2020 FAIR Data Management Plan - annex 1:

http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-data-mgt_en.pdf

- The ELIXIR Research Data Management Kit (RDMkit): **https://rdmkit.elixir-europe.org/**

Annex I: List of National Contacts

Name of participating organisation	*Country/Region*	*Regional/National contact*
Vlaams Gewest - VLAIO Flanders Innovation & Entrepreneurship, (FIO (VLAIO))	Belgium (Flanders)	Ariane Tiberghien Ariane.Tiberghien@vlaio.be Tel.: +32479291349
Service Public de Wallonie, (SPW EER)	Belgium (Wallonie)	Vinciane Grimard vinciane.grimard@spw.wallonie.be Tel.: +32 81 778 718
The Ministry of Health of the Czech Republic / Czech Health Research Council, (MZCR/AZVCR)	Czech Republic	Monika Kocmanova Monika.kocmanova@azvcr.cz Tel.: +420 778 973 186 Olga Laaksonen Olga.laaksonen@mzd.gov.cz Tel. : +420 604 786 141
Business Finland, (BFRK)	Finland	Norma Jäppinen norma.jappinen@businessfinland.fi Tel: +358 50 5577 012
Agence Nationale de la Recherche, (ANR)	France	Mylène Vaillancourt Tel.: +33 1 78 09 80 36 Mérick Machouri, Tel.: +33 1 72 73 06 72 EPPerMed@agencerecherche.fr
Health Research Board, (HRB)	Ireland	John-Mark Fitzpatrick HRB-JTCs@hrb.ie Tel.: +353 1 234 5000
Chief Scientist Office, Ministry of Health, (CSO-MOH)	Israel	Liron Even-Faitelson Liron.ef@moh.gov.il Tel.: +972-2-5082168
Israel Innovation Authority, (IRERD)	Israel	Sarah Chiche sarah.c@innovationisrael.org.il Tel.: +972 3 5118122
Italian Ministry of Health, (IT-MoH)	Italy	Maria Jose Ruiz Alvarez mj.ruizalvarez-esterno@sanita.it Simona Carmen Ursu sc.ursu@sanita.it
Latvian Council of Science, (LZP)	Latvia	Maija Bundule Maija.Bundule@lzp.gov.lv Tel.: +371- 26514481 Uldis Berkis Uldis.Berkis@lzp.gov.lv Tel.: +371-29472349
Research Council of Lithuania, (LMT)	Lithuania	Živilė Ruželė zivile.ruzele@lmt.lt Tel.: (+370) 676 14383
Comissão de Coordenação e Desenvolvimento Regional do Centro, (CCDRC)	Portugal (Centro Region)	Sophie Patrício ccdrc.projects@ccdrc.pt Tel.: +351 239 400 100

Name of participating organisation	*Country/Region*	*Regional/National contact*
Executive Unit for Research, Development and Innovation Higher Education Funding, (UEFISCDI)	Romania	Mihaela Manole mihaela.manole@uefiscdi.ro Nicoleta Dumitrache nicoleta.dumitrache@uefiscdi.ro
Centrum vedecko-technických informácií Slovenskej republiky, (CVTI SR)	Slovak Republic	Magdaléna Švorcová magdalena.svorcova@cvtisr.sk Tel.: (+421) 917 733 493 Erika Jankajová erika.jankajova@cvtisr.sk Tel.: (+421) 904 859 228
South African Medical Research Council, (SAMRC)	South Africa	Rizwana Mia Rizwana.Mia@mrc.ac.za Tel.: +27 21 938 0984
Consejería de Salud y Consumo de la Junta de Andalucía, (CSCJA)	Spain (Andalusia)	Alicia Milano Curto ep.fps@juntadeandalucia.es
Government of Navarre, (CFN)	Spain (Navarre)	Javier Larrea flarreal@navarra.es Tel.: +34 848 42 76 47
Sweden´s Innovation Agency, (VINNOVA)	Sweden	Casper Ullsten-Wahlund casper.ullsten-wahlund@vinnova.se Tel.: +46 8 473 32 06 Malin Eklund malin.eklund@Vinnova.se Tel.: +46 730 20 39 53
The Scientific and Technological Research Council of Turkey, (TUBITAK)	Turkiye	N. Selcan Türker selcan.turker@tubitak.gov.tr Tel.: +90 312 298 1760

Please note: The German Aerospace Center e.V. – Project Management Agency (DLR), Germany, is not participating in this call as a national funder, but is responsible for the central administration of the financial support for patient organisations or citizen organisations requesting budget from EP PerMed.

Annex II: Guidelines for patient organisations or citizen organisations

DLR, Germany is responsible for administering centrally the financial support for patient organisations or citizen organisations requesting budget from EP PerMed in this call.

For applications including patient organisations or citizen organisations that apply for financial support from EP PerMed, the submission of annex 6, the patient/citizen involvement plan, is mandatory at every stage to clarify the eligibility of funds.

Funding Organisation	**Deutsches Zentrum fuer Luft- und Raumfahrt e.V., (DLR) on behalf of EP PerMed**
Initial funding pre-commitment	**Multinational - Financial support patient organisations or citizen organisations**
Regional/National contact for the EP PerMed RITC2026	500.000 €
Contact for the EP PerMed RITC2026	PerMed@dlr.de
Eligibility of an organisation to act as a partner in this call	Patient organisations or citizen organisations only. Definition of eligible organisations: Patient organisations or citizen organisations are defined as not-for-profit organisations, which are patient or citizen focused, and where patients and/or carers and/or family members of patients or representatives of citizens (e.g. communities, populations) represent a majority of members in governing bodies. These are: • Umbrella organisations (e.g. representing either European organisations and/or national umbrella organisations for patients or citizens); • European organisations representing patient or citizen communities (i.e. representing national organisations or individual patients or citizens); and • National organisations representing patient or citizen communities.
Additional eligibility criteria	Criteria to be fulfilled by patient organisations or citizen organisations: • **Legitimacy:** the organisation should be formally established and registered as a not-for-profit organisation in one of the EU Member States or Associated Countries. • **Mission/objectives**: the organisation shall have its mission/objectives clearly defined.

	• **Structure**: Includes in its governing structure a designated representative legally authorised to sign a contract with DLR on behalf of EP PerMed.
	• **Accountability**:
	  • With proven activities such as patient/patient family/citizens support and/or advocacy activities and/or health research.
	  • Can demonstrate that its account system is able to trace all costs related to the project and archive these costs for a duration of 5 years after the end of EP PerMed.
	• **Transparency**:
	  • The organisation shall be financially independent, particularly from the private sector (max. 50% of funding from several companies) and disclose to EP PerMed its sources of funding both public and private by providing the name of the bodies and their individual financial contribution, both in absolute terms and in terms of overall percentage of the organisation budget. Any relationship with corporate sponsorship should be clear and transparent. This information shall be communicated to EP PerMed on an annual basis. The organisation should publish on its website the registered statutes, sources of funding, and information on their activities.
	To facilitate communication, a contact person shall be identified for each organisation.

Eligible costs	Max. 50.000 € per project (if more than one organisation representing patients or citizens is participating in one consortium the amount should be shared). The same organisation can max. participate in 3 applications submitted to the call. Expenses recognised as eligible are: personnel costs and operating expenses (travels, meeting, conference registration, etc.) but excluding office and IT equipment (workstation, mobile phone, tablets, etc.). Only staff costs are eligible, in proportion to the time spent on the project, with justification in the form of a time sheet. Operating expenses must be documented in the accounts. Expenditure on general, administrative and / or infrastructure costs is eligible respecting the maximum of 50.000 € total budget per project. All justifications and supporting documents are auditable by DLR or by any representative appointed by it during the project and a period of 5 years after the end of EP PerMed.
Funding of public-private partnerships allowed	Yes
Further guidance	For further information, applicants contact **permed@dlr.de**

Annex III: Information for applicants concerning regional/national eligibility criteria

Belgium (Flanders)

Funding Organisation	**Fonds Innoveren en Ondernemen, (FIO (VLAIO))**
Initial funding pre-commitment	1.000.000 €
Regional/National contact for the EP PerMed RITC2026	Ariane Tiberghien Ariane.Tiberghien@vlaio.be Tel. : +32479291349
Eligible institutions	Universities and research institutes as subcontractors of industry partners.
Additional eligibility criteria	Submission of the Flemish addendum via the E-tool of VLAIO latest simultaneously with the international deadline. Please contact Ariane Tiberghien in advance.
Eligible costs	Staffing costs, overhead costs, operating costs, third party services, investment costs. Extended eligibility check. Knowledge Hub costs need to be embedded in the project budget and are subject to VLAIO regulations.
Funding of public-private partnerships allowed	Yes
Further guidance	Documents required for submission at VLAIO: - Proposal - Template annex internationale en interregionale projecten **https://www.vlaio.be/nl/subsidies-financiering/onderzoeksproject/aanvraagprocedure-voor-de-subsidie-onderzoeksproject** - Template begrotingsaanvraag (same webpage) *1: Main applicant must be a company. Academic partner can only participate as research partner of the company. *2: Sufficient valorisation potential is a requirement

Belgium (Wallonia)

Funding Organisation	**Service Public de Wallonie, (SPW EER)**
Initial funding pre-commitment	1.000.000 €
Regional/National contact for the EP PerMed RITC2026	Vinciane Grimard **vinciane.grimard@spw.wallonie.be** Tel: +32 81 778 718
Eligible institutions	SMEs, large companies, universities, research centers
Additional eligibility criteria	- Walloon **partners should contact SPW at least 4 weeks before the pre-proposal deadline** and submit an application on the regional submission platform ONTIME. - Participants must be companies, universities/higher education institutions, accredited or certified research centers, established in the Walloon Region and conduct R&D activities within the project. - Walloon partners in the consortium must include at least one company, and the research budget of the Walloon partner companies must account for at least 40% of the total research budget of all Walloon partners. - Participants must be based in Wallonia, and the Walloon companies must have an operational unit in Wallonia. - Participants cannot receive any other public funding for the same activities. - Participants must have fulfilled their obligations under any previous support granted by the Region. - At the time of submission, companies must not be in difficulty according to the European Union guidelines. - Projects must focus solely on civilian technologies, products, processes, and services. - Participants must present an innovative R&D project that has a positive impact on the Walloon economy and aligns with the priority of the regional Smart Specialization Strategy (S3 Wallonia). - Participants must demonstrate their ability to carry out the tasks assigned to them in the project, to exploit its results, and to have a positive socio-economic and sustainable development impact on Wallonia. - The project cannot start at a TRL (Technology Readiness Level) lower than 3.

Eligible costs	Eligible costs are defined in the following guide : **Guide des dépenses éligibles**
Funding of public-private partnerships allowed	Yes
Further guidance	

Czech Republic

Funding Organisation	**The Ministry of Health of the Czech Republic / Czech Health Research Council, (MZCR/AZVCR)**
Initial funding pre-commitment	250.000 €
Regional/National contact for the EP PerMed RITC2026	Monika Kocmanova National coordinator on Health-related European Partnerships Phone: + 420 778 973 186 Email: **monika.kocmanova@azvcr.cz** Olga Laaksonen Head of the Science, Research, and Subsidies for Education Unit (MZCR) Olga.laaksonen@mzd.gov.cz Tel. : +420 604 786 141
Eligible institutions	Research Organisations, Enterprises. All eligibility rules and criteria can be found on the Czech Health Research website (**Výzva RITC2026 – AZV ČR**). It is recommended to contact the responsible person at the Czech Health Research Council (prior to submission regarding the eligibility criteria). Conditions for PAO funding – Patient organisations can receive direct funding if they take an active role in the project's research activities. This means they must contribute to specific research objectives (for example, by being involved in one or more work packages) and these types of research activities must be clearly described in their **statutes.**
Additional eligibility criteria	Prior to submission of the pre-proposal to EP PerMed, Czech researchers need to submit to the Czech Health Research Council the following documents: **1. Sworn Statement of a Legal Entity / Natural Person (mandatory)** **2. Sworn Statement for a Research Organisation (if relevant)** **3. Sworn Statement of composition consortium (only if SMEs or industry are involved in the project proposal from the Czech side)** **4. Application Form**

	Czech partners are required to complete a **national Application Form**, providing basic information about the applicant and any co-applicant(s), if applicable, including their respective budgets. It is necessary to list all national institutions involved in the project due to funding requirements. All these documents are available on the website at the Czech Health Research Council AZV ČR – **Výzva RITC2026 – AZV ČR**. Prior to submission of the full proposal to EP PerMed, Czech researchers need to submit to the Czech Health Research Council the following documents: **1. Documents** related to **professional competence**, depending on the nature of the project, must be provided in the form of a **Sworn Statement**, which will be available on the website at the Czech Health Research Council AZV ČR – **Výzva RITC2026 – AZV ČR**. **2. Updated Application Form** Czech partners are required to complete the **updated national Application Form**, providing basic information about the applicant and any co-applicant(s), if applicable, including their respective budgets. It is necessary to list all national institutions involved in the project due to funding requirements. According to Czech regulations, the main Czech applicant will sign a grant agreement with the national funding authority (MZCR) and, if there are any other Czech co-applicant(s), will subsequently enter into a cooperation agreement with them. At the international level (pre- or full proposal), it is preferable to list only one Czech partner – the main applicant**. If needed, it is possible to list more than one partner (in accordance with the call rules)**; however, at the national level, there will be one main Czech applicant while the remaining national institutions will act as co-applicants. Together, they must share the allocated project budget among themselves. The total project budget must not exceed 125.000 €.

	In case the projects of Czech participants are recommended for funding based on the results of the international evaluation and after the approval of the representatives of the funding authorities of the countries participating in the EP PerMed calls, the Ministry of Health of the Czech Republic / the Czech Health Research Council may ask the successful Czech participants to submit additional documents in order to issue a decision on the provision of purpose-special support according to the rules established by the Ministry of Health of the Czech Republic / Czech Health Research Council.
Eligible costs	All eligibility of costs, types and their caps can be found on the Czech Health Research Council (**Výzva RITC2026 – AZV ČR)**. It is **recommended** to contact the responsible person at the Czech Health Research Council (prior to submission regarding the eligibility criteria).
Funding of public-private partnerships allowed	Yes; however, in the private sector, the support intensities for each category of Enterprise and for each category of research are different. More information is available in the national documents.
Further guidance	**Výzva RITC2026 – AZV ČR**

Finland

Funding Organisation	**Innovaatiorahoituskeskus Business Finland, (BFRK), kirjaamo@businessfinland.fi**
Initial funding pre-commitment	2.000.000 €
Regional/National contact for the EP PerMed RITC2026	Norma Jäppinen, +358 50 5577012 **norma.jappinen@businessfinland.fi**
Eligible institutions	Academic partners, private for-profit partners, wellbeing services counties or HUS (and the project is implemented at a university hospital).
Additional eligibility criteria	Up to date funding conditions can be found from Business Finland's web service: **https://www.businessfinland.fi/en/for-finnish-customers/services/funding** and call text (once available). The call specific requirements/exceptions will be provided in the call text.
Eligible costs	https://www.businessfinland.fi/suomalaisille-asiakkaille/palvelut/rahoitus/ohjeet-ehdot-ja-lomakkeet/rahoitusehdot
Funding of public-private partnerships allowed	Yes
Further guidance	Funding is intended to companies', research organisations' and wellbeing service counties' (incl. HUS) R&D projects, including joint ones between them, which fulfill both the EP PerMed and Business Finland criteria **(see Business Finland call announcement in addition to abovementioned criteria).**

France

Funding Organisation	**Agence Nationale de la Recherche, (ANR), https://anr.fr/**
Initial funding pre-commitment	1.500.000 € Anticipated number of funded research groups: ~5
Regional/National contact for the EP PerMed RITC2026	Mylène Vaillancourt, +33 1 78 09 80 36 Mérick Machouri, +33 1 72 73 06 72 **EPPerMed@agencerecherche.fr**
Eligible institutions	Eligible institutions: ANR may fund research organisations and undertakings, as defined by the EC regulation on State aid for research, development and innovation (see the ANR funding regulations for further reference). As for research organisations, only those that have their primary establishment in France may be funded. As for undertakings, those that have their real head office in an EU member State and having an establishment (primary or secondary) in France may be funded. Within this framework, public research institutions (such as EPST, EPIC, Universities, University hospitals) as well as foundations can apply, in general for up to 100% of direct costs. This list is not comprehensive and funding rates vary. Enterprises may also be eligible: Funding rates vary based on the types of research and types of enterprises. For more information, please refer to the ANR **Financial Regulations**. Please note that companies with economic difficulties cannot receive ANR subventions. Please consult **https://anr.fr/fr/rf/** for full details. Private partners are asked to indicate their SIRET number in the pre- and full proposal template (partner description: "Project Consortium", "Other information").

Additional eligibility criteria	- ANR does not allow double applications nor provide double funding to finance projects or part of projects that have been funded through other national and international calls. ANR will cross-check the proposals submitted to ensure they have not been submitted to the ANR through other calls. - Large clinical trials are not funded by ANR. - Partners from countries subject to sanctions applicable to the research field by the European Union authorities are excluded from this call for ANR. ANR will declare Partners requesting its support ineligible if they apply with Partners established in these countries. At the date of publication, these exclusions concern Partners from the following countries and territories: Russia, Belarus, territories of Ukraine non-controlled by the Ukrainian government. This list may evolve in case of new sanctions decided by the European Union. - In keeping with the national PPST policy (Protection of the scientific and technologic potential of France) applicants to ANR should consult their local "FSD" (security and defence officer, where available) on their project before applying. Applications to ANR may be forwarded to the HFSD of the French Ministry of research and higher education for screening. A negative appraisal by the HFSD may cause ANR to reject the proposal.
Eligible costs	Eligible costs and rates of funding depend on the type of partners. Among others, eligible costs may include the following: personnel costs; equipment costs; consumables and animal costs; travel and subsistence costs; sub-contracting costs, if necessary, to carry out the proposed activities (sub-contracting costs max. 50% of requested budget per partner). For public research organisations, only personnel costs of fixed-term contracts are eligible (except for an EPIC in partnership with an enterprise). The ANR heading for «overheads» in the ANR financial regulations is « frais d'environnement ». 13,5% of the total eligible costs must be applied for if the partner is a public research organisation (or other organisation funded at "marginal" costs), or up to 68% of the total personnel costs and up to 7% of other costs for partners funded at full economic cost (such as enterprises). Please refer to ANR's financial regulations ("Règlement financier" ANR: **https://anr.fr/fr/rf/**) for full details. ANR has a maximum funding per partner for this call: a research team can be funded with a maximum amount of 330.000 € for a coordinating Partner and 280.000 € for a simple partner. The maximum funding available per project is 610.000 €. In the case that 3 partners apply in the same consortium, this amount must be shared between them. There is a minimum amount per partner: 15.000 €.
Funding of public-private partnerships allowed	Yes
Further guidance	Plan d'Action 2026: **https://anr.fr/fr/plan-daction-2026/** Règlement financier: **https://anr.fr/fr/rf/**

	ACCESS TO GENETIC RESOURCES AND BENEFIT-SHARING: Funded teams participating in projects falling within the scope of the regulations on access to genetic resources and benefit-sharing will be required to provide evidence to demonstrate compliance with these obligations and must ensure that all data relating to such genetic resources or associated traditional knowledge are kept in order to demonstrate that the necessary due diligence has been exercised. In case of a conflict of interpretation between the terms and conditions stated in this annex and the "*Modalités de participation*" and "*Règlement financier*", the latter shall prevail.

Ireland

Funding Organisation	**Health Research Board, (HRB)**
Initial funding pre-commitment	Up to 960.000 € Maximum funding per grant awarded to a partner: • ***For Partners in Ireland:*** 330.000 € direct costs; 430.000 € including overheads. • ***For Co-ordinators based in Ireland:*** 405.000 € direct costs (the additional 75.000 € is solely to support coordination-specific activities); 530.000 € including overheads
Regional/National contact for the EP PerMed RITC2026	John-Mark Fitzpatrick Email: HRB-JTCs@hrb.ie Tel: +353 1 234 5000
Eligible institutions	In order to be eligible to apply for funding, institutions must be an **approved HRB Host Institution** no later than two calendar months before the closing date of a call. See also the **Policy on Approval of HRB Host Institutions**.
Additional eligibility criteria	HRB cannot fund Irish Partner(s) that are not associated with a HRB Host Institution. The HRB will not provide funding for: • Proposals involving basic biomedical research • Research intended to create human embryos solely for the purposes of research or for the purposes of stem cell procurement, including by means of somatic cell nuclear transfer • Applications from individuals applying for, holding, or employed under funding received from the tobacco industry

	• Applications from individuals applying for, holding, or employed under funding received from the alcohol industry and related actors
Eligible costs	Funding available is inclusive of overheads & pension contributions. It will cover research-related costs including: (a)Salary related costs for research staff, (b) postgraduate stipends and fees (for Master's students only), (c) direct running costs, (d) Patient and Public Involvement (PPI) costs, (e) Small equipment costs (max. €10,000 total), (f) Travel, (g) FAIR data management costs, (h) Dissemination costs. Sub-contracting for the provision of a service can be covered up to a maximum of 20% of direct costs. This would need to conform with the Host Institution, National and EU procurement rules. Overheads are applied in accordance with the **HRB Policy on Usage of Overheads**. The HRB will contribute to the indirect costs of the research through an overhead payment of 30% of Total Direct Modified Costs (TDMC, excludes student fees, equipment and capital building costs) for laboratory or clinical-based research and 25% TDMC of desk-based research. For the caps on overheads see above section on "Maximum funder per grant awarded to a partner". HRB cannot provide funds to cover costs towards Technology Transfer, Patents or any commercialisation costs. For consortium co-ordinators, the additional 75.000 € (direct costs) must be allocated to coordination-specific activities and cannot cover equipment or consumables.
Funding of public-private partnerships allowed	Yes In projects where consortia include Enterprise partners, applicants applying to HRB for funding will be advised that funding awards will be subject to, and must comply with, State Aid rules and conditions of the European Commission General Block Exemption Regulation (GBER). The HRB cannot provide funding to Enterprise organisations as partners or collaborators. Organisations providing services for the project can be paid by the HRB recognised Host Institution via sub-contracting costs. Any procurement activities should adhere to national and EC procurement guidelines.

	All applicants should contact the HRB with any queries regarding the requirements of this policy.
Further guidance	Applicants seeking HRB funding must consult the HRB Guidance and FAQs for this call for important eligibility information: **HRB Funding Schemes**. The below documentation is required on submission: • New applicants to HRB for Joint Transnational Calls must submit a short form at submission to provide details on PI's track record for eligibility checks. • A letter of support will be required at submission stage for any Lead Applicants who do not have a permanent post at a HRB Host Institution. Please refer to the guidance on the HRB scheme page for further information. • At full proposal stage, applicants must complete HRB's Budget and Deliverables templates. These will be provided after invitation to submit a full proposal. HRB grant holders are required to submit grant reports as outlined in their grant contracts and the most recent **HRB General Terms and Conditions for Research Awards**. These include Annual and Final reports. **For full guidance, please refer to HRB's guidance on the HRB scheme page and contact the HRB for further information.**

Israel (CSO-MOH)

Funding Organisation	**The Chief Scientist Office of the Ministry of Health, (CSO-MOH)** **http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx**
Initial funding pre-commitment	Up to 320.000 €
Regional/National contact for the EP PerMed RITC2026	Liron Even-Faitelson **Liron.ef@moh.gov.il** +972-2-5082168
Eligible institutions	Israeli universities, research centres and hospitals CSO-MOH cannot fund private partners.
Additional eligibility criteria	PI should hold a Ph.D., M.D., D.M.D. or equivalent degree and employed by an eligible institution. Research will not be funded simultaneously by CSO-MOH on more than one grant (European network or national). Researchers can not apply for more than one grant from any European network funded by CSO-MOH or submit more than one proposal for any single program.
Eligible costs	Personnel (students, technicians. applicants excluded); animals, materials and consumables; travel (up to 5%); overheads 10%. No computers and permanent equipment. The maximum funding available from the CSO-MOH is 140.000 € per project. In cases where more than one Israeli research team participates in the same consortium, this amount must be shared between them. If an Israeli team serves as the coordinator of the consortium, an additional 40.000 € may be requested (for a total of up to 180.000 € per project).
Funding of public-private partnerships allowed	Yes
Further guidance	**Prior to submission, researchers must submit to CSO-MOH an abstract approved by their research authority including a detailed budget distribution.**

	This is not the consortia abstract, but an abstract describing the activity of the Israeli researcher within the consortia and a budget table for the Israeli researcher. A template for the abstract can be found **here**. **Lack of submission of an abstract can lead to disqualification of the whole application, as well as the consortium.** Bioethics approvals, if applicable, need to be submitted with the application or within 4 months following the approval of the application. Please see detailed instruction at: **http://www.health.gov.il/Subjects/research/International_cooperations/Pages/default.aspx**

Israel (ISERD)

Funding Organisation	**Israel Innovation Authority, (ISERD)**
Initial funding pre-commitment	Up to 500.000 €
Regional/National contact for the EP PerMed RITC2026	Sarah CHICHE +972 3 5118122 sarah.c@innovationisrael.org.il
Eligible institutions	• Israeli company engaged in R&D and is the owner of the Intellectual Property • Israeli Academia Institute (university or research institute) –when partnering with an Israeli industry (for-profit organization) member in the consortium. The Israeli company must commit to funding at least 10% of the researchers' budget.
Additional eligibility criteria	Companies must comply with the Israeli R&D Law, which includes being legally registered in Israel and keeping intellectual property developed with the grant in Israel. Please state here if you have any restrictions regarding the TRL or the research proposed. Pre-commercial applied research (TRL 2-5) **Israeli entities submission deadline for funding through the IIA by January 19 2026 17:00**
Eligible costs	Personnel Costs (Salaries of personnel directly involved in the R&D project), Equipment Usage (Depreciation or rental of equipment used for the project), Subcontracting and External Services, Materials and Consumables Up to 1 partner from academia and 2 from industry per consortia. The funding rate for SME & Industry (Private for Profit) is 66% (of approved budget). Israeli Academia Institute (university or research institute) –when partnering with an Israeli industry (for-profit organization) member in the consortium, in a rate of up to 80% of the approved budget, the Israeli industry to fund at least 10% of the Academia's approved budget, with a joint tasks/working package of the specific academia and industry members.

Funding of public-private partnerships allowed	Yes
Further guidance	**Israeli entities submission deadline for funding through the IIA by January 19 2026 17:00** IIA: Applicants are strongly recommended to contact the Funder Contact Persons before submitting a proposal and to refer to the National Announcement (link will be added once the final call topic is made public by EP PerMed RITC) where all national requirements for funding are defined. The application and eligibility are subject to the "Procedure for Financing Israeli Partners by the Innovation Authority under Sub-Programs for the European Framework Program" which will provide EP PerMed RITC open call topics. The procedures will be detailed in Hebrew in the Annex. Eligible applicants are entities that had submitted an eligibility form after the deadline of pre-proposal submission deadline and will be approved as eligible by Innovation Authority.

Italy

Funding Organisation	**Italian Ministry of Health, (IT-MoH)**
Initial funding pre-commitment	500.000 € (max. 400.000 € per project)
Regional/National contact for the EP PerMed RITC2026	Maria Jose Ruiz Alvarez mj.ruizalvarez-esterno@sanita.it Simona Carmen Ursu sc.ursu@sanita.it
Eligible institutions	Only IRCCS (Istituti di Ricovero e Cura a Carattere Scientifico) researchers are eligible to apply. Universities, other research Institutes, companies are not eligible.
Additional eligibility criteria	For the JTCs during the 2026, simultaneous participation of the same Principal Investigator (PI) in different proposals funded by the Ministry of Health is not permitted. A maximum of two Italian PIs may apply within the same project. Italian Patient Advocacy Organizations (PAOs) may receive funding as subcontractors of an IRCCS, provided they meet the EC eligibility criteria. The maximum subcontracting amount is limited to less than 10% of the total IRCCS budget. Italian SMEs may receive funding as subcontractors of an IRCCS, provided they meet the EC eligibility criteria. The maximum subcontracting amount is limited to less than 10% of the total IRCCS budget. Italian SMEs and PAOs may also participate in consortia as 'Collaborators,' using their own funds. Subcontracts are allowed only upon approval, by presenting via Workflow – code ER, a request together with the National pre-eligibility form, the latest 20 days before the deadline of the pre-proposal submission.
Eligible costs	Direct Costs: • Personnel (only temporary contracts or permanent contracts for the amount of hours dedicated to the project, <60%); • Consumables/Supplies;

	• Animals/Model costs; • Equipment (only on leasing or rent); • Travel (<30%); • Dissemination activities (<1%); • Publication costs: <2%; open access <5%; • Patients recruitment costs; • IT Services and Data Bases; • Coordination costs Indirect Costs: • Overhead (<10%, included in the total); Other indirect costs are not eligible. Transfer of eligible funds abroad is not allowed. Subcontracts are allowed only upon approval, by presenting via Workflow – code ER, a request together with the National pre-eligibility form, the latest 20 days before the deadline of the pre-proposal submission
Funding of public-private partnerships allowed	Yes
Further guidance	To expedite the eligibility check process, the Ministry of Health will grant eligibility clearance to applicants prior to the submission of proposals. For this purpose, applicants are **required to complete and return a pre-submission eligibility check form** to the IT-MoH, through their IRCCS, using the WFR System → ER communication code, **before submitting their proposal to the Joint Call Secretariat.** It is strongly recommended that the completed form be s**ubmitted at least 10 working days before the proposal submission deadline.** Applicants will receive written notification of their eligibility status. Please note that changes to acronyms or budgets provided in the pre-submission eligibility check are not allowed without agreement The pre-eligibility form can be downloaded here: **https://www.salute.gov.it/imgs/C_17_pagineAree_4441_0_file.pdf**

	At the national level, submission of annual scientific and financial reports will be required in accordance with the rules of the Ministry of Health (Ricerca Finalizzata). Further information on these rules may be requested from the national contact persons.

Latvia

Funding Organisation	**Latvian Council of Science, (LZP)**
Initial funding pre-commitment	600.000 €
Regional/National contact for the EP PerMed RITC2026	Maija Bundule Maija.Bundule@lzp.gov.lv Tel.: +371- 26514481 Uldis Berkis Uldis.Berkis@lzp.gov.lv Tel.: +371-29472349
Eligible institutions	Only the following **legal persons** are eligible: 1) Research institutions registered in the Latvian Registry of Scientific Institutions, e.g. - Research Institutes - Universities And must have the status of Research and knowledge dissemination organization (Regulation EC 651/2014) 2) Business enterprises entered into the Latvian Commercial registry as companies, assumed they are eligible to do the specific research and have specific capacity and resources to do the research in Latvia and have their main activity in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting requirements, in this case this is state aid. Two previous statements with sworn auditor's approval should be provided and they must reflect the correspondence to the regulation as well as prove the evidence of previous scientific activity and presence of capacity. Enterprises not having closed two annual financial periods are not eligible.
Additional eligibility criteria	Maximum funding allowed: 100.000 € per year per Latvian partner = grant of 0.3M for a 3-year project, 0.2M for a 2-year project Latvia allows max. 2 Latvian partners per proposal, they must be fully independent on legal, financial and personnel basis.

	Funding allocation must be coherent with the work plan. Applicants for State aid must send before the call deadline (both 1st and 2nd stages) to the e-mail address lzp@lzp.gov. lv, stating the acronym and the title of the project, applicant name and registration number in Latvia, the following document: a certification that the applying legal person does not correspond to the criteria laid down in laws and regulations to be subject to insolvency proceedings at the request of the creditor. It must be electronically signed by valid legal representative (s). Applicants for state aid can be supported with an intensity according to the Regulation 651/2014. Upon request applicants for State aid must provide all requested documents to evaluate the financial situation and financial viability. Undertakings in difficulty are not eligible for funding. (Regulation 651/2014) In case of State aid the undertakings are assessed for eligibility at each of the application stages and at the conclusion and during execution of the contract with LCS for project funding. If the eligibility criteria are not fulfilled, project funding cannot be approved or continued. Final audit according to the LCS regulations. LCS funds only research, no training nor implementation. LCS is not funding any activity beyond experimental development. Applicant must possess a Latvian bank account with a bank registered for operations at Bank of Latvia.
Eligible costs	• Personnel costs incl. taxes; • Consumables, animals; • Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted; • Equipment (only depreciation costs during project directly attributable to project tasks), only for equipment for which the beneficiary has directly incurred purchase costs; • Replaceable and fully consumable during project elements of equipment; • Travels (according to travel plan); • Indirect costs (up to 25% of direct costs excluding subcontracting).
Funding of public-private partnerships allowed	Yes Only in case industry-academia partnerships.

Further guidance	Support is provided according to Provisions Nr 259, 26.05.2015 of the Latvian Cabinet of Ministers **http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petnieciba-un-tehnologiju-joma** These provisions should be respected without exceptions. The maximum rates should respect the Provisions. The requirements in the provisions to specific applicant groups must be respected. Annual financial and scientific reporting is mandatory. To receive funding by LCS, Consortium agreement duly signed should be presented. Application for the state aid must be submitted before the starting date of the project which is stated in the consortium agreement. Enterprises shall provide audited statements of 2 previous closed financial periods on request. Final audit according to the LCS regulations.

Lithuania

Funding Organisation	**Lietuvos mokslo taryba / Research Council of Lithuania, (LMT)**
Initial funding pre-commitment	900.000 €
Regional/National contact for the EP PerMed RITC2026	Živilė Ruželė, Tel.: +37 067 614383 E-mail: **zivile.ruzele@lmt.lt**
Eligible institutions	Eligible institutions for funding include Lithuanian research and higher education institutions listed in the Register of Education and Research Institutions; public healthcare institutions; the Academy of Sciences, as referenced in the Law on Science and Studies; and other public state institutions such as national libraries, archives, and museums. The eligible beneficiary institution (grant holder) is responsible for managing the state budget funds allocated to the project in accordance with the applicable legal acts. It also represents the "project partners", if applicable. A "project partner" refers to a public or private legal entity that, together with the eligible beneficiary institution, contributes to the implementation of the project.
Additional eligibility criteria	The Principal Investigator (PI) must hold a PhD degree. Principal Investigators based in Lithuania may participate in only one proposal submitted under this call. The beneficiary institution is responsible for employing the Principal Investigator for the duration of the project. The PI's workload must be no less than 20 hours per month, multiplied by the number of months of the project's duration. Personnel costs must be calculated using the hourly rates approved by the Chairman of the Research Council of Lithuania. All other general rules for the competitive funding administered by the Research Council of Lithuania apply: **https://www.e-tar.lt/portal/lt/legalAct/0a8bead0577611e9975f9c35aedfe438/asr**
Eligible costs	Within a single project proposal, the maximum funding can be up to 300.000 € – for a mere consortium partner(s); up to 600.000 € – for a coordinator including the budget of additional partner(s).

	Only costs generated during the lifetime of the project, related to project are eligible: staff, travel, consumables, subcontracts, contractual research, consultancy, equipment and instruments, dissemination of results, data handling and analysis, overheads (up to 20 % from direct costs).
Funding of public-private partnerships allowed	Yes Our organisation (LMT) can provide financial support to for-profit private partners; however, this support cannot be provided directly. Any public or private legal entity may act as a "project partner" in collaboration with an eligible beneficiary institution (see section Eligible Institutions). Public entities participating as project partners receive funding through the grant holder (beneficiary institution), in accordance with applicable funding rules.
Further guidance	Submission of the proposal at the national level is not required at the application stage. However, following a positive funding decision, the grant-signing institution and the Principal Investigator (PI) must complete and submit a national document (template available [**at this link**]) containing the following information: - A more detailed planned budget - Foreseen dissemination and communication activities - Expected project outputs and contributions from the granted research team (e.g., scientific publications, patents, etc.) In addition, both midterm and final reports must be submitted at the national level in accordance with the requirements of the Research Council of Lithuania.

Portugal (Centro Region)

Funding Organisation	**Comissão de Coordenação e Desenvolvimento Regional, (CCDRC) – https://ris3.ccdrc.pt/index.php/iniciativas**
Initial funding pre-commitment	CCDRC funding commitment for this call is 300.000 € Maximum funding awarded: - 100.000 € for a regional consortium. - 150.000 € for a regional consortium with regional coordination (of the transnational project). If more than one regional applicant participates in the same consortium applying for CCDRC's funding, the combined funding demanded by all the regional applicants must not exceed the maximum financial threshold established above: for projects with a regional main applicant (150.000,00 €); for projects with regional applicants (100.000,00 €). Regional Main Applicants and/or Regional Project Applicants in the same consortium will therefore have to share the funding that will be granted by CCDRC.
Regional/National contact for the EP PerMed RITC2026	Sophie Patrício ccdrc.projects@ccdrc.pt +351 239 400 100
Eligible institutions	Non-entrepreneurial entities from the Research and Innovation System (ENESII), namely: a) Higher education institutions, their institutes and R&D units; b) State laboratories, associated or international laboratories based in Centro Region; c) Private non-profit institutions whose main purpose is R&D activities, including Collaborative Laboratories (CoLab) and Technology and Innovation Centres (CTI); d) Other public and private non-profit institutions that carry out or take part in research activities. Enterprises will not be considered eligible in the context of this call. **Note:** Only entities from NUTS II Centro or the ones that can assure that the investment will be made in Centro Region can apply to CCDRC's funding.

	All regional applicants must contact CCDRC's team before applying. To be considered an eligible partner, all applicants must comply with the requirements established in articles 123.º to 133.º, 138.º, 139.º (number 1) 141.º, 142.º, 144.º and 145.º of the Regulamento Específico da Área Temática Inovação e Transição Digital.
Additional eligibility criteria	The activities performed by regional stakeholders, within the projects, must: i) **Incorporate at least one activity of experimental development or industrial research**, according to the concepts presented in **r) and y) of article 3.º** of the Regulamento Específico da Área Temática Inovação e Transição Digital; ii) Fit the scope of the following types of operations: - Scientific Research and Technological Development (R&D); - Proofs of Concept; according to **a) and b) of article 136.º** of the Regulamento Específico da Área Temática Inovação e Transição Digital. To all other criteria and conditions not explicit in this annex, please consult Regulamento Específico da Área Temática Inovação e Transição Digital (**https://data.dre.pt/eli/port/103-a/2023/p/cons/20240808/pt/html**). When applying to the transnational call, all regional stakeholders must fill in and sign a Declaration: **https://ris3.ccdrc.pt/index.php/ris3-documentacao/declaracao-de-compromisso-saccct/download** The Declaration must be sent within 10 working days after the submission of the pre-proposal to ccdrc.projects@ccdrc.pt.
Eligible costs	Eligible costs must be verified in **article 143.º of the Regulamento Específico da Área Temática Inovação e Transição Digital** for the operation tipology "**IC&DT**" and "**Provas de Conceito**". The maximum funding rate for non-entrepreneurial entities from the Research and Innovation System (ENESII) is 85%. More details can be found in **article 141.º of the Regulamento Específico da Área Temática Inovação e Transição Digital**.

Funding of public-private partnerships allowed	Yes
Further guidance	To all other criteria and conditions not explicit in this annex, please consult Regulamento Específico da Área Temática Inovação e Transição Digital (**https://data.dre.pt/eli/port/103-a/2023/p/cons/20240808/pt/html**).

Romania

Funding Organisation	**Executive Unit for Research, Development and Innovation Higher Education Funding, (UEFISCDI)**
Initial funding pre-commitment	1.000.000 €
Regional/National contact for the EP PerMed RITC2026	Mihaela Manole mihaela.manole@uefiscdi.ro Nicoleta Dumitrache nicoleta.dumitrache@uefiscdi.ro
Eligible institutions	Eligible entities for funding are universities, public institutions, R&D national institutions, joint-stock companies, SME's and Large companies, NGOs (associations, foundations, etc.), others. Funding rates vary in accordance with state aid legislation. For more information: **https://uefiscdi.gov.ro/parteneriate-si-misiuni-europene** A person, as project manager, regardless of whether the Romanian institution is a project coordinator or partner, at the level of a transnational competition, can participate in a single project proposal.
Additional eligibility criteria	• 250.000 euro in case a Romanian institution is the Coordinator (together with other Romanian partner(s) – if it is the case); • 200.000 for one/all Romanian partner(s) participating in a proposal.
Eligible costs	a. Staff costs; b. Logistics expenses - Capital expenditure; - Expenditure on stocks - supplies and inventory items; - Expenditure on services performed by third parties cannot exceed 25 % of the funding from the public budget. The subcontracted parts should not be core/substantial parts of the project work; c. Travel expenses; d. Overhead (indirect costs) is calculated as a percentage of direct costs: staff costs, logistics costs (excluding capital costs and cost for subcontracting) and travel expenses. Indirect costs will not exceed 25 % of direct costs.

Funding of public-private partnerships allowed	Yes, in accordance with state aid legislation. For more information: **https://uefiscdi.gov.ro/parteneriate-si-misiuni-europene**
Further guidance	

Slovak Republic

Funding Organisation	**Centrum vedecko-technických informácií Slovenskej republiky (CVTI SR)**
Initial funding pre-commitment	600.000 €
Regional/National contact for the EP PerMed RITC2026	Magdaléna Švorcová, e-mail: magdalena.svorcova@cvtisr.sk, tel.: +421 917 733 493 Erika Jankajová, e-mail: erika.jankajova@cvtisr/sk, tel.: +421 904 859 228
Eligible institutions	Legal entities established in the Slovak Republic, such as public or private research and academic institutions, higher education institutions, SMEs, public sector entities, and other relevant organizations actively involved in research, development, and innovation. - Private sector entities (entrepreneurial/business sector) - Research institutions (e.g. the Slovak Academy of Sciences and its institutes) - Academic sector (e.g. universities and higher education institutions) - Public administration bodies and organizations established by them, including local and regional government authorities - Non-governmental non-profit organizations - Cluster organizations
Additional eligibility criteria	The proposed project activities must be in line with the priorities defined in the Research and Innovation Strategy for Smart Specialisation of the Slovak Republic 2021-2027 (SK RIS3 2021+), which serves as the strategic framework for research, development and innovation investments in Slovakia. All Slovak entities must have their contractual financial matters settled with CVTI SR by the end of 2029.
Eligible costs	- Personnel costs (salaries of researchers, technicians and other support staff employed by the beneficiary, to the extent that they are directly involved in the project, salaries of project management personnel and other essential positions necessary for the implementation and coordination of the project; - Costs of instruments and equipment

	- Costs for contract research, technical knowledge and patents purchased or licensed from external sources under market conditions, as well as costs for consultancy and equivalent services used exclusively for the project. All expenditures incurred by Slovak project participants must comply with: - Programme Slovakia, specifically Priority 1P1 Science, Research and Innovation, Specific objective RSO1.1: Development and enhancement of research and innovation capacities and the uptake of advanced technologies, Measure 1.1.3: Support for international cooperation in the field of research, development and innovation - The provisions of the State Aid Scheme to Support Partnerships in the Field of Research, Development and Innovation under the Programme Slovakia; - Strategy for Financing the ERDF, ESF+, CF, FST, and ENRAF 2021–2027.
Funding of public-private partnerships allowed	Yes
Further guidance	Applicants are strongly encouraged to contact the CVTI SR's contact point before submitting their proposals. After having been informed about the international funding recommendation, CVTI SR will require also submission of separate application for national funding via the national submission platform. The final formal funding decision is made by CVTI SR and only after the project was recommended for funding by the Partnership. Relevant national documents: Programme Slovakia, Research and Innovation Strategy for Smart Specialisation of the Slovak Republic 2021-2027 (SK RIS3 2021+), State Aid Scheme to Support Partnerships in the Field of Research, Development and Innovation under the Programme Slovakia. Useful links: **Programme Slovakia** **SK RIS3 2021+** **Strategy for Financing the ERDF,ESF+, CF, FST, and ENRAF 2021–2027**

South Africa

Funding Organisation	**The South African Medical Research Council, (SAMRC)**
Initial funding pre-commitment	450.000 € (appox.) (R9,200,000) Expected to fund 3 projects up to 150.000 € per project (excluding Value Added Tax (VAT) and including a 5% overhead cost)
Regional/National contact for the EP PerMed RITC2026	Rizwana Mia Senior Program Manager – Precision Medicine SAMRC- GRANTS INNOVATION & PRODUCT DEVELOPMENT Francie Van Zijl Drive, Parow Valley, 7501 Tel: +27 21 938 0984 Email: Rizwana.Mia@mrc.ac.za
Eligible institutions	South African universities, academic hospitals and other public or independent research organisations. This call will allow private entities to respond.
Additional eligibility criteria	Only South African citizens or permanent residents are eligible for SAMRC funding. **Private non-profit or Private for-profit entities such as Small Medium Micro Enterprise's (SMME's) registered as a South African company under the Company's Act are eligible to apply.** https://www.gov.za/sites/default/files/gcis_document/201903/423041gon399.pdf The company's SMME status must meet the requirements as stated by the definition of the South African National Small Enterprise Act, No. 102 of 1996. The eligibility criterion for a company to gain access to public entity funding is subject to meet the following requirements: i. Submit a valid CIPC company registration certificate and (Broad-Based-Black-Economic Equity (BBBEE) certification status ii. Submit a tax clearance certificate issued by the South African Revenue Service. iii. Submit a financial status report (this should include a company balance sheet and financial income/ expense statements), to show that its financial status is adequate to hold project funding and the entity follows an audit pro-cess for usage and monitoring of funds.

	iv. The company directors may also be subject to a personal credit status check. A due diligence process will be executed to verify such information at the time of the award.
Eligible costs	Allowable costs include the following (all direct line items must be auditable): • Personnel: Soft-funded posts for individuals working on the project (e.g. post-docs, students, technicians, project managers) will be funded, provided an accurate estimation of time allocation is provided and they are not already funded from other means. • Consultants: These may include both local and/or foreign consultants who provide a service or capability that is not available among the project partners but is essential for the completion of project deliverables. • Equipment: Partial or full support for the cost of equipment may, in some instances, be requested, provided that it is directly required for the project. A budget limitation may apply. • Laboratory costs: consumables and other direct laboratory or research costs. • Sub-contracts: These may be to any local or international organization that provides a service or capability that is not available among the project partners but is essential for the completion of South African project deliverables. • Travel and accommodation that is directly related to the execution of the project. • Institutional overhead: An indirect costs rate of 5% is allowed. If research equipment is purchased using SAMRC funding, unless specified otherwise by the specific funding mechanism, it becomes the property of the host institution. Under no circumstances may equipment become the property of the individual researcher to whom the funding was allocated. The equipment may not be removed from the host institution and/or transferred to another institution without the express written approval of the host institution and concurrence by the SAMRC. The institution must take responsibility for any necessary maintenance of and insurance on the equipment. Budgets must be aligned to achievement of milestones and deliverables. The disbursement schedule will proceed with an upfront payment upon signature of the SAMRC funding agreement. Subsequent disbursements are subject to project progress based on achievement of milestones and deliverables, as well as adequate usage (up to 70%) of the previous disbursement.

Funding of public-private partnerships allowed	Yes, subject to the due diligence process stated above.
Further guidance	Non-allowable costs include the following: • Salaries of permanent or fixed term staff, e.g. tenured staff, professors etc., that are fully covered by the host institutions as well as permanent staff members from private entities. • Purchase or construction of a building. • Rental costs for space that is owned by the institutions/ private entities participating in the project. • Recruitment or retrenchment costs for staff. • Purchase of office furniture. The South African Applicant will have to complete separate annexures for the SAMRC Funding agreement. Annexure A- Adapted South African Project Proposal template and Annexure B -Project Budget template will be provided for completion upon award. These two annexures will be appended to the SAMRC Funding agreement and utilized to monitor and evaluate project progress. The SAMRC has a bi-annual reporting procedure. Each reporting period will be followed by the submission of progress and finance reports. The SAMRC will adhere to annual funding disbursements. Private entities will be subject to six monthly disbursement schedules. For more detail on the general terms and conditions for SAMRC funding please refer to the SAMRC terms and conditions of funding, use the following link: **Microsoft Word - SAMRC Terms and Conditions of Funding 2024 Clean** **Any publications press releases and other documents which include results obtained in the project must acknowledge the funding source as follows: "*Research reported in this [publication/press release] was supported by the South African Medical Research Council with funds received from the South African Department of Science and Innovation*". Any publications that do not include this acknowledgement will not be accepted as outputs of the project.**

	Requirements on data and repositories: The SAMRC strongly encourages open access to research outputs/data to be made available in recognized publicly available databases. The SAMRC conforms to Plan S -supported by cOAlition S, an international consortium of research funding and performing organisations. Plan S requires that, from 2021, scientific publications that result from research funded by public grants must be published in compliant Open Access journals or platforms. **Regulatory and Ethical Compliance:** All SAMRC grantees are required to obtain approval for any research involving human or animal subjects or samples therefrom the appropriate institutional review board or ethics committee and provide the SAMRC with a copy of such approval prior to undertaking the research. This requirement extends to all sites participating in the research. Any such research must, in addition to ethical approval compliance, be conducted in accordance with the generally accepted principles of "Good Clinical Practices", which shall include but not be limited to, requiring prior informed consent from the human subjects and shall be conducted in accordance with all applicable national and international regulations and guidelines pertaining to research involving human subjects, management of data confidentiality, research involving animals, use or release of genetically modified organisms, research use of recombinant DNA, and/or use of any organism, substance or material considered to be a biohazard, including adherence to all applicable standards for transport of specimens, both locally and internationally, as appropriate. This also applies to the development of data repositories and the ongoing compliance to the Protection of Personal Information Act 4 of 2013. **Compliance to South African Regulation:** **Ownership of any intellectual property (IP)** and associated rights arising from SAMRC-funded projects (Foreground IP) shall be determined in accordance with the provisions of the Intellectual Property Rights from Publicly Financed Research and Development Act, 51 of 2008 and associated regulations as amended from time to time (IPR Act) and the institution's Intellectual Property Policy. The institution/ private entity is obliged to appropriately protect, manage, and commercialize the Foreground IP in accordance with all applicable provisions of the IPR Act and, in consultation with the SAMRC. The institution / Principal Investigator is required to report any Foreground IP developed to the SAMRC as part of the reporting requirements.

	Project's processing/ handling any personal information will each comply with the provisions of the **PROTECTION OF PER-SONAL INFORMATION ACT 4 OF 2013 (POPIA).** The institution/ private entity is obliged to appropri-ately protect and man-age all personal information. **Additional Partnership criteria applies to this call and requires you to complete the pre-eligibility check form https://redcap.link/Pre-EligibilityCheck-RITC2026**

Spain (Andalusia)

Funding Organisation	**Regional Ministry of Health and Consumer Affairs of Andalusia – Consejería de Salud y Consumo de la Junta de Andalucía, (CSCJA), ep.fps@juntadeandalucia.es**
Initial funding pre-commitment	250.000 €
Regional/National contact for the EP PerMed RITC2026	Alicia Milano Curto **ep.fps@juntadeandalucia.es**
Eligible institutions	Eligible organisation must be Andalusian Non-profit entities registered as Agents of the Andalusian Knowledge System (Registro de Agentes Andaluces del Conocimiento) with research and innovation activity in Biomedicine and Health Sciences, i.e.: Research managing foundations of the Andalusian Public Health System. Eligibility criteria established in **Orden de 10 de agosto de 2023** de la Consejería de Salud y Consumo de la Junta de Andalucía.
Additional eligibility criteria	• Principal investigators must be linked through a civil servant, statutory or labour relationship with the applicant or performing centre. For Health Research Institutes (Institutos de Investigación Sanitaria, IIS), the link may be with any of the public or private law entities that are part of the IIS provided that the entity meets all the specific requirements determined in each action, and, in any case, be personnel assigned to the IIS. • More than one partner from Andalusia may participate in the same project. • A PI can only participate in one application per call. • For receiving regional funding, the final funding decision issued by the corresponding program's decision-making body must be accredited. • The duration of the projects shall be determined by the corresponding JTC. In any case, this period shall be stated in the award resolution.
Eligible costs	a. **Goods and services**: consumables, bibliographic material, equipment rentals, software licenses and external services.

	b. **Personnel costs**: specifically hired for the project, including salaries, employer Social Security contributions, legally established compensation and other duly justified expenses derived. c. **Travel, accommodation and subsistence** according to the maximum amounts of compensation for service established in Decree 54/1989, of March 21, on compensation for service of the Junta de Andalucía, exclusively for people who are part of the research group or hired under the funded project. Exceptionally, any expense outside these amounts, or for people other than those listed before, must be authorised by the granting body. d. **Registration fees for congresses or conferences** for the presentation and dissemination of the results. Publication costs e. **Other expenses** duly justified and necessary for carrying out the project. f. **Indirect costs** 21% g. **Subcontracting costs**: cannot exceed 50% of the funding and need prior authorization from the granting body. Nor Scientific aspects nor the management of the project should be subcontracted. The following **are NOT considered eligible** expenses - Equipment or Equipment repair and maintenance - Items or amounts that, after analysis, are not considered justified - Amounts paid to persons participating in the project, except for expenses necessary for special attention to patients that involve compensation for their participation in the project not derived from an employment relationship. The sum of the funding or income received for the same purpose may in no case exceed the cost of the funded activity.
Funding of public-private partnerships allowed	Yes. In the case of private partners, please be aware that CSCJA itself is only providing funds to private not-for-profit research institutions in the terms described at "Eligible Institutions" section.
Further guidance	The projects must respect the fundamental principles established in national and international declarations, protocols and conventions on research ethics, as well as respect the requirements established in national and regional legislation in the field of biomedical research, development and innovation, personal data protection and bioethics.

	When the results are not susceptible to protection of industrial or intellectual property rights, the scientific publications resulting from the funding granted must be made available in open access, in accordance with article 37 of Law 14/2011, of June 1.

Spain (Navarre)

Funding Organisation	**Gobierno de Navarra, (CFN), http://www.navarra.es**
Initial funding pre-commitment	200.000 € (anticipated number of funded research groups: 3-4)
Regional/National contact for the EP PerMed RITC2026	Regional Ministry of Industry and of Digital and Ecologic Business Transition Service of Support in European Initiatives Parque Tomás Caballero Nº1 Edificio "Fuerte del Principe II" 31006 Pamplona, Spain Javier Larrea Tel.: +34 848 42 76 47 **flarreal@navarra.es**
Eligible institutions	Universities, Research Institutes, technological centers and companies that comply with points 2.2 and 2.5 a) and b) from the Resolution 466E/2024, of the 30 December. It can be found in the Official Navarrese Gazette #14, 13th February 2025 (**https://bon.navarra.es/es/anuncio/-/texto/2025/30/7**). The compliance of these requirements has to be assured during the whole project. A document with a declaration of responsibility regarding these requirements has to be signed. The template is available at: **https://www.ep-permed.eu/funding-projects/calls/ritc2026/**. If grant is higher than 30.000€, companies must fulfil payment deadlines according to State Law 3/2004, of 29th December which Establish Measures of Combating Late Payment In Commercial Operations. The way to assure this Requirement will be according to Official Regulations and has to be consulted to Government of Navarra.
Additional eligibility criteria	**The duration of the project must be up to 3 years.**
Eligible costs	The following expenses will be eligible:

	a) Personnel expenses when it is not a Public Research Institute or Public University. The maximum eligible cost will be 45 € per hour. b) Expenses of the materials used in the project. c) Depreciation expenses of equipment, patents and utility models, to the extent and during the period in which these assets are used for the project. d) Expenses of external collaborations of Universities, Technological Centres and other companies that carry out R & D tasks related to the project and provide technical knowledge. e) Expenses derived from the use of Singular Scientific and Technical Infrastructures (ICTS) of national or European scope. f) Application fees for patents generated by the project. This expense will not be eligible for large companies. g) Other expenses directly related to the project and effectively applied to its realization, provided that they can be identified as specifically employed in the project and that they can be assigned individually to it. This section includes travel expenses, dissemination of results expenses (maximum 4000€), documentation preparation expenses (maximum 1500€) and audit expenses. h) Indirect costs up to 15% of the Personal expenses. The following expenses will not be eligible, even if they are related to the activities of the project: a) Personnel training expenses. b) Administrative expenses and office supplies. The maximum outsourcing rate for the project cannot be bigger than 50%.
Funding of public-private partnerships allowed	Yes
Further guidance	Maximum Funding rate: According to Commission Regulation (EU) No 651/2014 article 25. Companies:

	Company size			
R&D&i Category	**Small**	**Medium**	**Large**	**Specific conditions**
Industrial research	80%	80%	75%	Involves effective collaboration between undertakings and the results of the research and development project are widely disseminated in the member states of the project consortia
Experimental development	70%	60%	50%	

Certified SINAI agent, according to the Regional Law 15/2018, of 27th June, of Science and Technology (see register list (https://administracionelectronica.navarra.es/RegistroSinai.Internet/Public/Agente/Index): 100%

Sweden

Funding Organisation	**Sweden´s Innovation Agency, (Vinnova), www.vinnova.se**
Initial funding pre-commitment	The total funding commitment is 24 million SEK (approximately 2.100.000 €). The maximum amount of funding per consortium for Swedish participation is 3 million SEK for 1 Swedish partner and 5 million SEK for 2 or more Swedish partners.
Regional/National contact for the EP PerMed RITC2026	Casper Ullsten-Wahlund, +46 8 473 32 06, **casper.ullsten-wahlund@vinnova.se** Malin Eklund, +46 730 20 39 53, **malin.eklund@Vinnova.se**
Eligible institutions	Universities, public research institutes, healthcare providers, enterprises and non-profit organisations.
Additional eligibility criteria	The grants paid out by Vinnova must be administrated by a Swedish organisation. They need to be a Swedish legal entity with a Swedish organisation registration number. See **Vinnova's general terms and conditions for funding | Vinnova**
Eligible costs	Universities, public research institutes and public healthcare providers may receive funding of up to 100 % of their eligible costs, provided that the activity in the project is part of their non-economic activities. Vinnova follows the state aid rules for economic activities (enterprises). In this call enterprises can apply for funding either industrial research or experimental development. We can provide support according to GBER as well as the regulation on minor support (EU 2023/2831). If minor support is used, you need to include a minor support certificate. For more information see **Rules for funding | State aid for economic activities | Vinnova** Eligible costs are defined in: **Vinnova's general terms and conditions for funding | Vinnova**.
Funding of public-private partnerships allowed	Yes
Further guidance	Detailed national eligibility rules and guidance **can be found here.** Vinnova requests that a parallel application is uploaded into Vinnovas portal no later than 1 week after the international call has closed. Vinnova follows the

	principle of public access to official records according to Swedish law. Vinnova performs a confidentiality review before releasing any documents. For more information see: **Requesting an official document | Vinnova** A Swedish partner may apply for a maximum of 3 million SEK. If more than one Swedish partner applies for financing, the total amount cannot exceed 5 million SEK.

Turkiye

Funding Organisation	**The Scientific and Technological Research Council of Turkiye, (TÜBİTAK)**
Initial funding pre-commitment	400.000 €
Regional/National contact for the EP PerMed RITC2026	N. Selcan Turker, PhD 0090 3122981760 selcan.turker@tubitak.gov.tr
Eligible institutions	Applicants can apply from universities (public and private), research institutes, public and private corporations. Foundations/Associations are not eligible. For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK. TÜBİTAK-funded costs of each grant shall be issued and managed by TÜBİTAK in accordance with the rules of TÜBİTAK 1071 Program.
Additional eligibility criteria	TÜBİTAK national rules dictate a certain upper limit per project and per applicant type, however, these limits will be defined once the initial funding commitment is defined. Moreover, Turkish applicants must add and indicate their Project Incentive Bonus and Institutional Share budgets on top of the national cost of the project itself. For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK. We do not have any TRL restrictions.
Eligible costs	Eligible types of funding under this programme are limited to personnel costs, travel and subsistence, equipment, consumables and subcontracting/services and a fixed amount of Overhead budget per each Turkish applicant. Projects intended to build infrastructure cannot be supported. For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.
Funding of public-private partnerships allowed	Yes

Further guidance	For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.